Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Discovery Laboratories, Inc. Announces Completion Of $45.0 Million Public Offering
Discovery Laboratories, Inc. announced that it has completed its previously announced public offering to sell an aggregate of 16,071,429 shares of its common stock under Discovery Labs' previously filed registration statement that was declared effective by the Securities and Exchange Commission on June 21, 2011. The offering remains subject to the underwriters' 30-day option to purchase up to an additional 2,410,714 shares of common stock to cover over-allotments, if any. Each share was issued and sold at a public offering price of $2.80 per share. Lazard Capital Markets LLC acted as the sole book-running manager for the offering, Stifel Nicolaus Wesiel acted as co-lead manager, and ROTH Capital Partners LLC acted as co-manager.
Latest Developments for Discovery Laboratories Inc
- Discovery Laboratories Inc Announces Completion Of $14.25 Million Public Offering
- Discovery Laboratories Inc Prices $14.25 Million Public Offering of Common Stock
- Discovery Laboratories Inc Receives FDA Recommendations And Request For Clarification Regarding Recently-Submitted SURFAXIN (lucinactant) Updated Product Specifications
- Discovery Laboratories Inc Appoints New Chief Executive Officer
Latest Key Developments in Biotechnology
- Cyprotex plc Sees H1 2013 Guidance To Exceed Board's Expectations; Sees FY 2013 Operating Profit Guidance In Line With Current Market Expectations
- Prana Biotechnology Ltd's PBT434 Drug Candidate Shows Potential As Next-Generation Diseasemodifying Treatment In Parkinson’s Disease
- Pharmacyclics Inc Announces Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma
- Repros Therapeutics Inc Announces Pricing Of Public Offering Of Common Stock
- Share this
- Link this
- Digg this


Follow Reuters